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Introduction: Short-term ventricular assist device (VAD) implantation is a life-saving
procedure in patients with refractory cardiogenic shock. The present paper provides our
experience with patients we were able to bridge from this critical condition directly to
heart transplantation.
Method: Our group comprises 11 patients implanted a Levitronix CentriMag short-term
ventricular assist device from April 2009 to October 2012 as a bridge to heart transplanta-
tion. Six (55%) patients received a biventricular assist device while ﬁve (45%) had a left-
ventricular assist device implanted. The mean age of patients was 41.2 years (20–63 years).
Our group of patients included eight men (73%). The underlying diagnoses included dilated
cardiomyopathy (5 patients), coronary heart disease (4 patients), infective endocarditis,
and primary graft failure (1 patient each). Prior to implantation, all patients received high
doses of inotropes, and eight (73%) patients had mechanical ventilatory support. Six (55%)
patients showed laboratory signs of liver and kidney failure, and metabolic acidosis.
Results: The mean time from VAD implantation to putting the patient on the urgent
waiting list for heart transplantation was 7.6 days (1–54 days) depending on organ function
recovery. The mean duration of mechanical circulatory support was 26.7 days (8–72 days).
The mean time from inclusion into the waiting list to transplantation was 19.1 days (4–52
days). One-month, six-months and one-year survivals post-transplant were 91%, 82%, and
73%, respectively.
Conclusion: Implantation of the CentriMag short-term ventricular assist device in patients
with refractory cardiogenic shock and otherwise grim prognosis markedly increases their
chances for survival. Given the relatively short waiting time in the Czech Republic, the
CentriMag ventricular assist device can thus serve as a direct bridge to heart transplanta-
tion.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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The CentriMag ventricular assist device (Levitronix, Zurich,
Switzerland) has been used for the management of patients
developing heart failure after cardiac surgery, post-transplant
graft failure, and those experiencing acute heart failure of
various etiology refractory to conventional therapy. The
procedure is used mostly as a bridge to recovery in patients
expected to restore their cardiac function, or as a bridge to
decision in those with an unclear outcome following cardio-
pulmonary resuscitation. There have been occasional reports
of implantation of the device as a bridge to transplantation
[1–6]. While, in the European Union, the device has been
approved for short-term support for up to 30 days; there have
been reports of their safe use for as long as 3 months [7]. The
present paper reports on our experience obtained in a group
of patients bridged from cardiogenic shock directly to heart
transplantation.2. Material and methods
Between 2007 and 2012, a Levitronix CentriMag ventricular
assist device was implanted in 25 patients in our center; of
this number, three (12%) for post-cardiotomy failure (after
cardiac surgery), one (4%) patient had it implanted as right-
ventricular support following the implantation of the Heart-
Mate II, a left-ventricular assist device (LVAD) (Thoratec,
Pleasanton, CA, USA), three (12%) patients received the device
for cardiac graft failure post-transplant, and 18 (72%) patients
in acute heart failure with signs of cardiogenic shock. The
device was explanted in ﬁve patients reaching cardiac func-
tion recovery. One patient had subsequently long-term
implantation of the HeartMate II device. There were eight
deaths during the study period.
The present paper reports on 11 patients who had been
bridged directly to heart transplantation. Six of them (55%)
received a biventricular assist device while ﬁve (45%) had aTable 1 – Characteristics of patients prior to CentriMag VAD im
LVAD (5 patients )
Males (%) 80
Age (yrs) 41 (28–59)
MVS (%) 80
CVVH (%) 20
LVEF (%) 14.772.5
RVEF (%) 27.573.5
LVEDD (mm) 66.576.7
MPAP (mmHg) 36.576.7
S-urea (mmol/L) 12.7710.4
S-creatinine (mmol/L) 151.7776.8
AST (mmol/L) 2.473.3
ALT (mmol/L) 2.773.6
Bilirubin (mmol/L) 13.8736.0
Lactate (mmol/L) 3.172.8
ALT—alkaline transaminase; AST—aspartate transaminase; CVVHD—continuous
—end-diastolic left ventricular diameter; LVEF—left ventricular ejection fraction; M
fraction.LVAD implanted. The mean age of our patients was 41.2 years
(20–63 years); eight (73%) patients were males. Underlying
diagnoses included dilated cardiomyopathy (5 patients), cor-
onary heart disease (4 patients), infective endocarditis and
primary graft failure (1 patient each). Prior to implantation, all
patients were receiving pharmacological circulatory support
using a combination of 2–3 high-dose inotropes or vasopres-
sors, eight (73%) patients were on mechanical ventilatory
support, and six (55%) showed laboratory signs of liver and
kidney failure, and metabolic acidosis. The patients' preo-
perative characteristics are summarized in Table 1. A LVAD
alone was only implanted in the absence of right-heart and
multiorgan failure as, in these cases, optimal blood ﬂow and
adequate perfusion of all tissues can be much better obtained
with biventricular support.2.1. Surgical technique
The surgical approach was median sternotomy in all cases.
Given the patients' hemodynamic instability, the procedure
was undertaken on-pump. Cardiac decompression using an
extracorporeal circuit appreciably facilitates insertion of can-
nulae into the left atrium and pulmonary artery [8]. For LVAD
implantation, the inﬂow cannula is inserted into the left
atrium anteriorly to right pulmonary veins and the outﬂow
cannula is inserted into the ascending aorta via the vascular
prosthesis. Direct insertion is associated with a higher risk for
bleeding [9]. When implanting a right-ventricular assist
device, the inﬂow cannula is inserted into the right atrium
and outﬂow cannula is inserted into pulmonary artery. The
cannulae exit preperitoneally through the abdominal wall.
Progressive increase in revolutions is attempted to achieve a
minimal cardiac index of 2.2–2.4 L/min. All patients have
intraoperative esophageal echocardiography to rule out intra-
cardiac shunts and aortic insufﬁciency and to check, before
the end of the procedure, proper placement of the cannulae
during cardiac chamber decompression (Fig. 1).plantation.
BiVAD (6 patients ) In total (11 patients )
67 73
44 (20–63) 43 (20–63)
67 73
33 27
12.075.7 13.377.4
10.0718.0 21.1715.5
69.0714.4 66.6711.4
40.678.3 39.177.3
13.773.4 13.678.7
159.8773.3 155.9772.1
3.572.4 3.472.8
2.172.3 2.573.1
34.7716.3 29.0728.5
4.375.1 4.074.2
veno-venous hemodialysis;MVS—mechanical ventilatory support; LVEDD
PAP—mean pulmonary artery pressure; RVEF—right ventricular ejection
Fig. 1 – Biventricular assist system CentriMag.
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After the procedure and stopping blood loss into drains, antic-
oagulation was achieved by continuous heparin infusion. The
dose was corrected every 4 h to reach target values of activated
partial prothrombin time (aPTT) of 60–100 s. When testing for
cardiac function recovery based on ﬂow rates decreasing to an
approx. 1 L/min, the target value aPTT is 80–100 s.
Their state of consciousness allowing, the patients were
extubated as soon as possible and rehabilitation started. As
movement of patients was considerably limited by the length
of the tubes, the role of nursing and controlled rehabilitation
is most crucial. Of the 11 patients, only two could be
transferred to the intermediate care unit.
2.3. Heart transplantation
In all cases, heart transplantation was performed using the
bicaval technique. The actual procedure is technically quite
challenging, particularly because of the risk of bleeding and
adhesions changing in nature with the interval since implan-
tation. Care should be taken when manipulating with the
cannulae, especially those in the left atrium, as they may be
coated with tiny closely sticking thrombotic plaques posing a
non-negligible risk of embolism [7].3. Results
The mean time of mechanical support using the CentriMag
short-term ventricular assist device was 26.7 days (8–72 days).
The mean time from ventricular assist device implantation to
patient inclusion into the urgent waiting list for heart trans-
plantation was 7.6 days (1–54 days) depending on organ func-
tion recovery without infectious or neurological complications.
Once put on the waiting list, the mean time to transplantation
was 19.1 days (4–52 days).
The mean time of mechanical ventilation was 10.8 days
(1–45 days). Reintubation was required by four patients, and
long-term mechanical ventilation via a tracheostomic can-
nula was necessary in two. Renal failure required continuousveno-venous hemodialysis (CVVHD) in eight (72%) patients.
Five patients (45%) had reoperation for bleeding. Four (36%)
patients developed infectious complications (sepsis in two,
and gangrenous cholecystitis and bronchopneumonia in one
each). Another serious complication was gastrointestinal
bleeding in three (27%) patients requiring temporary discon-
tinuation of heparin-based anticoagulation; luckily enough,
the patients did not develop thromboembolic complications.
At least one serious complication was experienced by nine
(81%) patients who thus made up one of the most proble-
matic groups of patients in our center.
The mean age of our patients was 33 years (16–53 years).
The causes of donor brain death included subarachnoidal
hemorrhage (5 donors), cranial trauma (4 donors), and
hypoxic brain injury (2 donors). The mean time of cold
ischemia was 179 min (76–254 min). The mean time of stay
at the ICU post-transplant was 14.5 days (1–63 days).
The mean time of total stay at the ICU was 40.2 days (15–117
days). Total hospitalization time was 72.4 days (15–121 days).
Revision for post-transplant bleeding was necessary in
one patient with an extremely thin graft aortic wall even-
tually requiring a Bentall procedure.
One patient experienced a major disorder of sternotomy
healing. It was a patient with infective endocarditis as the
primary diagnosis, and heart transplantation was the ﬁfth
cardiac surgery procedure within two months. Using a vacuum
assisted closure (VAC) system, we were able to successfully heal
the wound and the patient was discharged on hospitalization
day 95 to home care.
There were three deaths among these 11 patients reported
in this paper. One patient died in the early post-transplant
period from refractory right-heart graft failure. The cause of
death of another patient was ischemic stroke at ﬁve months
post-transplant, and the third patient died following subar-
achnoidal hemorrhage with a malignant brain tumor at seven
months post-transplant. Overall, the survival rates thus were
91%, 82%, and 73% at one month, six months and one year
post-transplant.4. Discussion
The ﬁrst report on our experience with the CentriMag short-
term ventricular assist device was published two years ago [10].
Implantation of the CentriMag device is relatively simple and
quick. A major advantage is optional biventricular support in
patients in the worst condition, that is, with bilateral heart
failure and multiorgan failure. Compared with mechanical left-
ventricular assist devices for long-term circulatory support
(e.g., HeartMate II or Heartware), the CentriMag is relatively
inexpensive, a major consideration in patients early after
resuscitation with unclear neurological outcome. Besides, the
CentriMag device is capable of generating a sufﬁcient ﬂow rate
(up to 10 L) so even patients with a high BMI will have adequate
organ perfusion allowing for recovery of their function. In
patients with normalized organ function (particularly that of
the liver and kidney), devoid of signs of increased inﬂammatory
activity and in a satisfactory neurological status, we take the
opportunity to bridge them directly to heart transplantation.
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increased risk for surgical or infectious complications in patients
undergoing long-term implantation of LVAD, we ﬁnd direct
bridging to heart transplantation a better alternative. The
procedure appreciably shortens the time of bridging to heart
transplantation as it is recommended not to perform transplan-
tation in patients receiving long-term assist devices before 10–12
weeks of support. Another consideration not to be disregarded is
the risk of thromboembolic complications potentially develop-
ing after extraction of the cannulae (especially those inserted
into the left atrium) [7]. Although there have been reports of
experience with use of the device for over three months and
pump exchange at a six-weeks interval, the CentriMag ventri-
cular assist device pump is certiﬁed for use for up to 30 days in
the European Union [7]. In our group of patients, one had pump
exchange at the above interval without the need for sedation or
surgery. With this simple and well tolerated procedure, we were
able to safely prolong the time of support.
Our patients were relatively young (mean age, 41 years). This
may have contributed to successful organ function recovery,
rehabilitation with the implanted device, and the fact the
patient become a suitable candidate for heart transplantation.
The main limitation to the concept of direct bridging the
patient to heart transplantation using a short-term ventricu-
lar assist device is the availability of the cardiac graft. In the
USA, where the probability of ﬁnding a heart for transplanta-
tion within 30 days is virtually zero, the CentriMag device is
used as a bridge to long-term LVAD implantation [8]. By
contrast, Haj-Yahia et al. from the United Kingdom published
their experience with direct bridging of patients to transplan-
tation using the CentriMag device with a mean time of
support of 43 days, and waiting time of 31 days [7]. In our
group of patients, the mean waiting time after inclusion into
the urgent waiting list was 18 days. In patients with a low
probability of having a transplantation within a short period
of time (those with high BMI, high panel reactive antibodies,
rare blood group) it is appropriate to consider, after successful
recovery from multiorgan failure and with satisfactory right
ventricular function, early implantation of long-term LVAD.5. Conclusion
Implantation of the CentriMag short-term ventricular assist
device in patients with refractory cardiogenic shock and
otherwise grim prognosis signiﬁcantly increases their
chances for survival. Given the relatively short waiting timesin the Czech Republic, the CentriMag device can be employed
for bridging the patient directly to heart transplantation.Acknowledgments
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